An Interventional, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Efficacy of ZP9830 Administered for 8 Weeks in Participants With Plaque Psoriasis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months).
• Participants who have ≥ 2 vulgar psoriatic plaques.
• BMI within the range 18.0-35.0 kg/m2 (inclusive).
• Further inclusion criteria apply.
Locations
Other Locations
Netherlands
Centre for Human Drug Research
RECRUITING
Leiden
Contact Information
Primary
Clinical Operations
clinicaltrials@zealandpharma.com
+45 88 77 36 00
Time Frame
Start Date: 2026-07-22
Estimated Completion Date: 2027-04
Participants
Target number of participants: 32
Treatments
Experimental: ZP9830
The experimental arm is divided into two treatment arms with different dose frequencies.
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Collaborators: ICON Clinical Research, Centre for Human Drug Research, Netherlands
Leads: Zealand Pharma